GE HealthCare Q1 2026 results

What happened: GE Healthcare's stock plunged 11.3% following its Q1 2026 earnings report. The company's margins were squeezed by rising costs, leading to a reduction in EPS guidance. Long-cycle sales delayed the impact of price increases on revenue, while inflationary pressures added to the headwinds. Despite this, the company reported a 7.4% increase in total revenues, with organic growth contributing 2.9%. Jim Cramer discussed GE Healthcare among other stocks, acknowledging the company's potential despite market confusion.

Market impact: The healthcare sector, particularly medical device manufacturers, felt the reverberations. Investors reassessed their positions in GE Healthcare and other companies in the space, with some favoring other up-and-coming stocks due to GE Healthcare's margin pressures. The delay in revenue growth from price increases also raised concerns about the company's ability to pass on costs to customers.

What to watch next: GE Healthcare's Q2 2026 earnings, scheduled for late July, will provide further insight into the company's cost management strategies and revenue growth trajectory. Additionally, investors will closely monitor inflation data to gauge the broader impact on the company's margins. Lastly, regulatory decisions on GE Healthcare's pipeline products, such as its imaging systems, will also influence the narrative around the stock.